Corey Goodman is a scientist, educator, and entrepreneur. Dr. Goodman is currently a Managing Partner of venBio Partners LLC, a venture capital firm focused on innovative therapeutics for major unmet medical needs. Dr. Goodman is Chair of the board of two biotechnology companies (Second Genome and Alexo), and a member of the board of two others (Checkmate and NFlection). He chaired another company (Labrys) until its acquisition by Teva.
He spent 25 years as Professor of Biology at Stanford University and then Evan Rauch Chair of Neurobiology at Berkeley, where he was Howard Hughes Medical Institute Investigator, Head of the Neurobiology Division, and co-founder and Director of the Wills Neuroscience Institute. Since moving into the private sector, he is currently Adjunct Professor of Neuroscience in the Wills Neuroscience Institute at U.C. Berkeley. He received his B.S. degree from Stanford University, his Ph.D. from University of California Berkeley, and trained as a Helen Hay Whitney postdoctoral fellow at U.C. San Diego.
Dr. Goodman is an elected member of the National Academy of Sciences, American Academy of Arts and Sciences, and American Philosophical Society, and recipient of many honors including the Alan T. Waterman Award, Canada Gairdner Biomedical Award, March-of-Dimes Prize in Developmental Biology, Reeve-Irvine Research Medal, and Dawson Prize in Genetics from Trinity College Dublin.
Dr. Goodman co-founded seven biotechnology companies (including Exelixis, Renovis, Second Genome, Labrys, and Alexo) and led one of them (Renovis) as CEO from a private to public company until its acquisition. He was recruited as President and founder of Pfizer’s Biotherapeutics and Bioinnovation Center and a member of Pfizer’s executive leadership team.
Amongst his many public policy roles, Dr. Goodman is a member of the University of California Innovation Council, a member of the board of the Pacific Institute, former Chair of the National Research Council's Board on Life Sciences, former Chair of the California Council on Science and Technology, and past President of the McKnight Endowment Fund for Neuroscience.
Karim Dabbagh was appointed President and CEO of Second Genome in 2018, which he joined as the Chief Scientific Officer in 2014. Prior to that, he served as Vice President of R&D at Pfizer where he led the Immunoregulation department, an R&D group focused on innovative approaches to elicit homeostatic immune responses for the treatment of immune related disorders. At Pfizer, he also led External R&D Innovation for Immunology, Neurosciences and Cardiovascular/Metabolic Therapy Areas. Before joining Pfizer, Karim was the founder of Modus BioMedicine, a biotechnology company focused on treatments for transplantation and autoimmune disease. Leading to that, Karim spent nine years at Roche in Inflammation Discovery Research. Karim obtained his PhD in Biochemistry from University College, London and his BSc (Hons) in Biotechnology from Imperial College, London. He completed postdoctoral fellowships at the Cardiovascular Research Institute at the University of California, San Francisco and at Stanford University where he worked on elucidating the role played by the microbiome in the hygiene hypothesis.
Mike is a General Partner and Team Leader of Lightstone Ventures (LSV) and focuses on investments in the biopharmaceutical and medical device sectors. He is based in the firm's Menlo Park, CA office, where he also serves as a General Partner at Advanced Technology Ventures (ATV). His representative investments include Altura Medical (acquired by Lombard), Ardian (acquired by Medtronic), EndoGastric Solutions, GI Dynamics (ASX: GID), Holaira, MicroVention (acquired by Terumo), Plexxikon (acquired by Daiichi Sankyo), PowerVision, Second Genome and TranS1 (NASDAQ: TSON).
Featured on the Forbes Midas List of top technology and life science investors, Mike is a recognized thought leader in the industry and a frequent speaker at healthcare conferences. He serves as a Lecturer at the Amos Tuck School of Business Administration at Dartmouth College where he also sits on the Tuck MBA Advisory Board. In addition, Mike is a Director on the National Venture Capital Association (NVCA) Board of Directors where he is active in helping to shape policy affecting both innovation and healthcare. Lastly, Mike has been heavily involved with several programs at Stanford University including the Stanford Biodesign Program and, more recently, the Stanford Center for Clinical and Translational Research and Education (Spectrum) where he currently serves as a Member of the Oversight Committee.
Earlier in his career, Mike served as the Director of Business Development for Inhale Therapeutic Systems (now Nektar Therapeutics, NASDAQ: NKTR), a venture-backed pulmonary drug delivery company that went public in 1994. At Inhale, Mike led partnering activities with a number of pharmaceutical and biotechnology companies in the U.S., Europe, and Japan. Mike also was a Principal at The Wilkerson Group, a leading management consulting firm focused exclusively on healthcare. At The Wilkerson Group, Mike helped establish the firm's offices in London and San Francisco.
Elaine V. Jones, Ph.D. joined Pfizer Venture Investments as Executive Director, Venture Capital in 2008. She is responsible for making and managing venture investments for Pfizer and currently oversees the PVI investments in Autifony Therapeutics Ltd. (London, UK), CytomX Therapeutics (NASDAQ: CTMX), Mersana Therapeutics (Cambridge, MA), Merus B.V. (Utrecht, The Netherlands), MIRNA Therapeutics (Austin, TX), MISSION Therapeutics (Cambridge, UK), Nimbus Therapeutics LLC. (Cambridge, MA), Quartet Medicine (Cambridge, MA), Second Genome (San Francisco, CA), and Ziarco Pharma (Canterbury, UK). Elaine brings 16 years of venture capital experience and a strong background in research and product assessment, built on her significant experience in pharmaceutical drug discovery and business development to the PVI team.
Most recently, Elaine was a General Partner with the venture fund, EuclidSR Partners. There, she was responsible for the fund’s investments in Acurian, Fluidigm, InnaPhase and Targacept.
Prior to joining ESR, Dr. Jones began her private equity career in 1999 at S.R. One, GlaxoSmithKline’s venture fund, where she managed investments including Adolor, Avantium, Nucleonics, Scynexis and Vicuron. Previously, she served as Director of Scientific Licensing for SmithKline Beecham and was a research scientist in SmithKline Beecham Pharmaceutical R&D.
Dr. Jones is a graduate of Juniata College and received her Ph.D. in Microbiology from the University of Pittsburgh.
Jason Lettmann is a Partner of Lightstone Ventures as well as a Partner on the Life Science team at Morgenthaler Ventures. Jason invests in biopharmaceutical and medical device companies and brings over 15 years of operating and venture experience in the life science sector. Jason currently serves on the Board of Directors of Alexo Therapeutics, FIRE1, Promedior, Ra Pharmaceuticals, Relievant Medsystems, Second Genome, and Vapotherm. Jason also recently established Lightstone’s Europe office in Dublin, Ireland, to expand the firm’s investment activities to Europe and currently serves as Director of Lightstone Capital Management Ireland Ltd.
Before joining Morgenthaler in 2009, Jason was a Vice President at Split Rock Partners where he focused on early-stage venture investments in medical devices and the life sciences. During his time at Split Rock, Jason was involved with the firm’s investments in Ardian (acquired by Medtronic), Cabochon Aesthetics (acquired by Ulthera), Atritech (acquired by Boston Scientific), EBR Systems, Entellus Medical (NASDAQ: ENTL), Evalve (acquired by Abbott Labs), and Miramar Labs. Jason was also previously a co-founder and on the Board of Tarsus Medical before its acquisition by Integra Life Sciences in 2013 as well as involved with the founding of Zyga Technologies.
Prior to Split Rock, Jason’s experience includes tenure with Guidant Corporation’s Compass Group which focused on corporate venture investing and business development, as well as a consultant with Accenture’s Health and Life Science practice, where he advised clients across the medical device, pharmaceutical, and healthcare payer sectors. Jason also previously worked as a Genetic Research Analyst at the University of Iowa Hospitals and Clinics.
Brad is co-founder and CEO of Cerevance, a drug discovery company focused on brain diseases with sites in Massachusetts and the United Kingdom. He previously co-founded Envoy Therapeutics in 2009, serving as Chief Executive Officer prior to its acquisition by Takeda Pharmaceutical Company in 2012. Earlier, Brad co-founded Perlegen Sciences, Inc. and served as its Vice Chairman and Chief Executive Officer.
Brad also currently serves on the Boards of two cancer companies, Arvinas and Presage Biosciences, and two non-profits, the A-T Children’s Project and Global Genes. He is also the Chair of the Network for Excellence in Neuroscience Clinical Trials External Oversight Board at the NIH.
Carole Nuechterlein has headed the Roche Venture Fund since 2001. Prior to her current position, she worked in the pharmaceutical/biotech industry as an attorney for ten years. She joined Roche from SangStat in Fremont California where she was General Counsel.
She currently serves as a director at AveXis, Inc. and Lysosomal Therapeutics, Inc. and Second Genome and a board observer on Allakos and 23andMe. Carole also led the investments on Alios, Ambit, Ambrx, Conatus, Envoy, Nereus & Pharmasset and served as a board observer for all of these except Pharmasset.
She has a BA from Valparaiso University and a JD from University of Michigan.
More information on the Roche Venture Fund can be found at www.venturefund.roche.com.
Jill Carroll is a Principal with SR One, Ltd., the corporate venture capital arm of GlaxoSmithKline. Jill joined SR One in 2011 with a background in biotech partnering and commercial development. Prior to SR One, Jill was responsible for Corporate Development at Dynavax Technologies (NASDAQ: DVAX), where she was involved in multiple pharma partnering deals and substantial private and public financings. Previously, Jill was a consultant specializing in health care at Clearview Projects and Mercer Management Consulting.
Jill received her B.S. in Chemistry from Duke University, and her M.S. in Biochemistry, Cellular and Molecular Biology from Johns Hopkins University. Jill is a member of the Board of Directors of Second Genome, Tioma Therapeutics and is involved with SR One's investments in AGTC, eFFECTOR, Principia and Progyny.